EGFR and neoplasm: In comparison to the FDA-approved anti-EGFR mAb cetuximab which had no significant effect, LA1 dramatically blocked tumor cell aggregation and cluster formation of two TNBC PDX models, TN1 and TN2, labeled by L2G and L2T respectively (Figure 1B and Figure S1A).